Community Engagement in the Development of an Abbreviated Mindfulness-Based Cognitive Therapy Intervention for Depression in Older African American/Black Breast Cancer Survivors (Community Minds)

The purpose of this research study is to develop and test an intervention designed to improve mood and reduce symptoms of depression.

开始日期2024-11-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT06537869 / Not yet recruitingN/AIIT

The New Internet Generation: iCBT Treatment for Seniors With Mild-moderate Depression - a Pragmatic Randomised Controlled Trial in the Primary Care Context

This clinical trial aims to evaluate the potential benefits of internet cognitive behavioural therapy (iCBT) for elderly patients with mild/moderate depression and compare its effectiveness with the current treatment as usual (TAU) at primary care centres (PCCs).
The specific aims are to study if:
iCBT is as effective as TAU in reducing depressive symptoms iCBT is as effective as TAU in increasing quality of life iCBT is as effective as TAU in increasing the function in patients >65 years and older with mild/moderate depression attending primary care, with the perspective of 36 months.
Participants will:
Work with the iCBT program (10-12 weeks) or become TAU at their PCCs. Followed-up at 3, 6, 12, 24 and 36 months of their symptoms, quality of life and function.

开始日期2024-09-01

申办/合作机构

University of Gothenburg

[+1]

NCT06091527 / RecruitingN/AIIT

Treating Major Depression With Yoga Mono-therapy: 12-Week Randomized Controlled Trial

The goal of this single-center, single-blind, randomized, controlled, parallel group, interventional trial is to evaluate antidepressant efficacy of yoga monotherapy of 12-weeks duration in 180 adults meeting diagnostic criteria for mild-to-moderate major depression at the Zuckerberg San Francisco General Hospital. Researchers will compare the yoga interventions to an education control intervention on holistic healthcare.

开始日期2024-09-01

申办/合作机构

The University of California, San Francisco

100 项与轻度抑郁相关的临床结果

登录后查看更多信息

100 项与轻度抑郁相关的转化医学

登录后查看更多信息

0 项与轻度抑郁相关的专利（医药）

登录后查看更多信息

134

项与轻度抑郁相关的文献（医药）

2024-08-01·Neuroscience

Increased malondialdehyde and nitric oxide formation, lowered total radical trapping capacity coupled with psychological stressors are strongly associated with the phenome of first-episode mild depression in undergraduate students

Article

作者: Maes, Michael ; Almulla, Abbas F ; Tunvirachaisakul, Chavit ; Michelin, Ana Paula ; Brinholi, Francis F ; Matsumoto, Andressa K ; Vasupanrajit, Asara ; Barbosa, Décio S ; Semeão, Laura de O

Undergraduate students are frequently afflicted by major depressive disorder (MDD). Oxidative and nitrosative stress (O&NS) has been implicated in the pathophysiology of MDD. There is no information regarding whether mild outpatient MDD (SDMD) and first episode SDMD (FE-SDMD) are accompanied by O&NS. The current study compared lipid hydroperoxides (LOOH), malondialdehyde (MDA), advanced protein oxidation products, nitric oxide metabolites (NOx), thiol groups, plasma total antioxidant potential (TRAP), and paraoxonase 1 activities among SDMD and FE-SDMD patients versus healthy controls. We found that SDMD and FE-SDMD exhibit elevated MDA and NOx, and decreased TRAP and LOOH as compared with controls. There was a significant and positive correlation between O&NS biomarkers and adverse childhood experiences (ACEs), and negative life events (NLEs). O&NS pathways, NLEs and ACEs accounted for 51.7 % of the variance in the phenome of depression, and O&NS and NLS explained 42.9 % of the variance in brooding. Overall, these results indicate that SDMD and FE-SDMD are characterized by reduced total antioxidant defenses and increased aldehyde and NOx production. The combined effects of oxidative and psychological stressors are substantially associated with the manifestation of SDMD.

2024-05-27·Psychology, Health & Medicine

Catastrophizing moderates the relationship between pain severity and depressive symptomatology among women with endometriosis

Article

作者: Zarbo, Cristina ; Secomandi, Rita ; Malandrino, Chiara ; Betto, Enrico ; Bellia, Adriano ; Brugnera, Agostino ; Candeloro, Ilario ; Compare, Angelo ; Frigerio, Luigi

The link between pain severity, depressive symptomatology and catastrophizing among women with endometriosis is still under-investigated. The aim of this study was to (i) evaluate differences in depressive symptomatology between women with and without endometriosis; (ii) investigate if pain severity is associated with depressive symptoms; and (iii) test if catastrophizing moderates the link between these two variables. A total of 172 women with a diagnosis of endometriosis and 62 healthy controls volunteered for this cross-sectional study. Depressive symptomatology, pain severity, and catastrophizing were assessed.Compared to healthy controls, women with endometriosis were more likely to score above the cutoff for depressive symptomatology, with 60.5% of the latter being classified as having a subthreshold depression or minor depression and 15.7% as having moderate or severe major depression. Pain severity was significantly associated with depressive symptoms even after controlling for several covariates. Finally, the moderation model suggested that among patients with endometriosis, the relationship between pain severity and depressive symptomatology depended on the level of catastrophizing, with this association being stronger for high levels of the moderator.Mental health practitioners working with women with endometriosis may consider those who report high levels of pain severity and of catastrophizing at high risk of depression and are advised to promote adaptive coping strategies among patients to foster a better adaptation to this chronic disease.

2024-05-01·Early Intervention in Psychiatry

The performance of K6 as a screening tool for mood disorders: A population‐based study of the São Paulo metropolitan area

Article

作者: Corassa, Rafael Bello ; Andrade, Laura Helena ; Sarti, Thiago Dias ; Viana, Maria Carmen ; Bruzeguini, Meirielli Vieira ; Wang, Yuan-Pang

AbstractAimThe use of screening instruments allows the detection of psychological and behavioural manifestations there are often not identified in users of health services. We evaluated the performance of the Kessler Psychological Distress Scale (K6) in identifying mood disorders (MD), using the Composite International Diagnostic Interview (CIDI) as gold‐standard, in a population‐based sample (n = 5037) of adult residents of metropolitan São Paulo.MethodsSensitivity, specificity, positive and negative predictive values, and accuracy were calculated to assess the performance of K6 in detecting 30‐day CIDI MD. All cut‐points for each disorder were analysed using the Youden index and the area under the receiver operating characteristic curve (AUC), and the best cut‐points were identified. Cronbach's alpha was calculated to assess internal consistency.ResultsIn total, 5.5% respondents screened positive for any MD (95% IC 4.84–6.14). A good detection performance was observed for all MD, with AUC values for any MD of 0.91 (95% IC 0.89–0.92), ranging from 0.80 (95% CI 0.71–0.98) for minor depression to 0.93 (95% CI 0.87–0.98) for bipolar I disorder. Best cut‐points for each MD were identified, with overall sensitivity and specificity of 88.8% and 80.2%, respectively. Cronbach's alpha was 0.83.ConclusionsK6 is a good screening tool for MD in the Brazilian population. It is a brief and easy to use instrument that can promote the early identification and treatment of MD, reducing the burden of mental illness.

项与轻度抑郁相关的新闻（医药）

2024-10-25

·生物谷

睡眠呼吸暂停竟暗藏抑郁危机？！Transl Psychiatry｜OSA患者的昼夜节律基因表达失调与其抑郁症状的严重程度密切相关

昼夜节律是人体内部的“生物钟”，通过细胞内的基因网络调节生理和行为过程，使人体能够适应昼夜变化。这一机制主要由“昼夜节律基因”控制，这些基因通过反馈回路的节律性转录调节其他基因的表达，从而调控新陈代谢、免疫系统、内分泌系统以及多种生理功能。阻塞性睡眠呼吸暂停（OSA）是一种常见的慢性睡眠呼吸障碍，表现为睡眠碎片化和间歇性缺氧。这种病理现象会扰乱患者的昼夜节律，影响其生理节律机制。此外，OSA患者中抑郁症的共病率较高，研究表明约有17%的OSA患者患有抑郁症，其症状与抑郁症患者相似，如白天嗜睡、焦虑、注意力不集中等。OSA患者中昼夜节律的失调可能是其抑郁症状的潜在原因。近日，波兰罗兹医科大学Agata Gabryelska研究团队在Transl Psychiatry发表了题为Circadian clock dysregulation: a potential mechanism of depression in obstructive sleep apnea patients的研究论文，发现OSA患者的昼夜节律基因表达失调与其抑郁症状的严重程度密切相关，尤其是PER1基因的表达变化可能成为预测OSA患者抑郁症状的重要指标。该研究结果强调了将昼夜节律基因作为干预目标的重要性，为开发基于昼夜节律调整的OSA及其相关情绪障碍的治疗方法提供了新思路。研究背景本研究旨在探讨OSA患者昼夜节律基因表达与抑郁症状之间的关系，并寻找可能影响抑郁症严重程度的预测因素。研究共纳入184名受试者，他们在实验过程中进行多导睡眠监测（PSG），并在晚间和次日早晨分别采集外周血样本。根据呼吸暂停-低通气指数（AHI），受试者被分为OSA组（AHI > 5）和对照组（AHI < 5）。从外周血白细胞中提取RNA，并使用定量实时PCR（qRT-PCR）分析BMAL1、CLOCK、PER1、CRY1、NPAS2、NR1D1等基因的表达水平。同时，受试者在PSG后完成失眠严重程度指数（ISI）、Epworth嗜睡量表（ESS）和蒙哥马利-阿斯伯格抑郁症量表（MADRS）的问卷调查，用于评估失眠、白天嗜睡和抑郁症状的严重程度。研究结果研究结果显示，OSA患者的昼夜节律基因在早晨的表达水平普遍高于晚间，除了NPAS2基因外，对照组的CRY1、PER1和NR1D1基因在早晨的表达水平也显著高于晚间。此外，OSA患者的昼夜节律基因早晨表达与抑郁症状的严重程度（通过MADRS评分评估）呈正相关，而晚间基因表达与抑郁症状无显著关联。通过多变量线性回归分析发现，失眠严重程度（ISI评分）、主观振幅评分（AM评分）以及PER1基因早晨表达是OSA患者抑郁症状加重的预测因素。该回归模型解释了54.3%的抑郁症状变异性（p < 0.001），其中失眠严重程度对抑郁症的影响最大。图：对照组和 OSA 组之间的昼夜节律时钟基因比较受试者特征 OSA患者的基线特征显示，OSA组的中位AHI为25.8次/小时，OSA组与对照组相比，体重指数（BMI）和男性比例更高，且OSA患者夜间觉醒频率显著增加。OSA患者中，38名患者无抑郁症状，75名为轻度抑郁，15名为中度抑郁，2名为重度抑郁。研究讨论认为，OSA患者的昼夜节律基因表达失调与抑郁症状的严重程度密切相关。这一发现与以往的研究结果相符，已有研究表明昼夜节律失调可能是抑郁症发病的潜在机制，特别是PER1基因的早晨表达与抑郁症状的严重程度呈正相关，表明其可能是OSA患者抑郁症状的预测因素。此外，昼夜振幅较大以及失眠症状严重的OSA患者更易出现抑郁症状。研究还指出，昼夜节律失调和OSA的病理机制可能是双向作用的，未来需要进一步研究以深入探讨昼夜节律基因失调对OSA和抑郁症的相互影响，从而揭示其潜在的生理机制，并开发针对性的治疗方法。总之，本研究揭示了OSA患者昼夜节律基因失调与抑郁症状严重程度的相关性，特别是PER1基因表达可能是抑郁症预测的重要指标，这为OSA患者个性化治疗提供了新的思路。未来可以通过调节昼夜节律缓解抑郁症状，为OSA和抑郁症共病机制的深入研究和治疗策略的开发提供了重要依据。参考文献： Gabryelska, A., Turkiewicz, S., Kaczmarski, P. et al. Circadian clock dysregulation: a potential mechanism of depression in obstructive sleep apnea patients. Transl Psychiatry 14, 423 (2024). https://doi.org/10.1038/s41398-024-03134-0 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

2024-08-26

·奇点网

少时发炎，小心长大代谢“发疯”

*仅供医学专业人士阅读参考大量研究数据表明，炎症和精神障碍之间存在关联，抑郁症、躁郁症和精神病谱系障碍患者的炎症水平有所增加，促炎状态和焦虑症之间存在关联。经过长时间积累，人们逐渐观察到，精神疾病患者通常心脏代谢结果不佳，肥胖、2型糖尿病和心血管疾病的发病率是一般人群的1.4-2倍。虽然生活方式和药物使用可以解释其中部分原因，但是还不足以完全解释精神疾病与心脏代谢之间的关系，首次精神病发作的年轻患者胰岛素抵抗的发生率也高于一般人群。因此，也有人猜测，早期炎症可能与成年后精神疾病和心脏代谢疾病风险增加有关。伯明翰大学的研究人员研究了儿童和青少年时期炎症的纵向影响。研究发现，在9-17岁期间，儿童越早出现低度全身性炎症与24岁时出现特定精神疾病和心脏代谢疾病风险增加有关，最高风险可增加360%。研究发表在《JAMA·精神病学》杂志上。研究数据来自英国大型雅芳父母与儿童纵向研究（ALSPAC）。通过C反应蛋白（CRP）评估炎症水平，分别记录儿童9岁、15岁和17岁时的CRP数据，在24岁时检查精神和心脏健康结果，精神健康结果包括精神病体验（PE，过去6个月内出现幻觉、妄想和思维干扰）、精神病、抑郁症和广泛性焦虑症，通过胰岛素模型评估（HOMA2）检查胰岛素抵抗。共有6556名参与者纳入分析，50.4%为女性。按照炎症增长趋势（LCGA，潜在类别增长分析）分为3组，参考组占95%，CRP水平稳定保持在较低状态；早期峰值组（EPG）占3%，CRP水平一直较高，最高值在9岁时发生；晚期峰值组（LPG）占比为4%，CRP水平也一直较高，最高值在17岁时发生。CRP变化轨迹加权和调整后的逻辑回归模型显示，EPG与24岁时精神病风险增加360%有关（OR，4.60），与24岁时PE风险增加130%有关（OR，2.30）。分别来看，EPG与24岁时患严重抑郁症风险增加337%有关（OR，4.37），没有发现与轻度抑郁、轻度躁狂和广泛性焦虑症的关联。没有发现LPG与精神健康结果的关联。CRP轨迹与精神和心脏代谢结果的关系在心脏代谢方面，EPG与24岁时较高的HOMA2评分有关，表明个体存在胰岛素抵抗或者胰岛β细胞功能异常。总的来说，研究确定了儿童和青少年时期两种不同类型的低度全身性炎症轨迹，分别在儿童中期和青少年晚期达到CRP峰值。儿童中期达到炎症峰值与青年时期的精神和心脏代谢结果有关，支持儿童和青少年时期慢性低度炎症可能是成年期精神和心脏代谢疾病共病的常见风险因素的假设。同时，作者补充道，“我们仍然无法证明炎症是否是这些疾病的致病因素，但很明显，炎症的出现早于精神疾病和可能相关的代谢功能障碍，需要进一步研究其驱动机制。”参考文献：https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2822343本文作者丨王雪宁

临床结果

2024-07-15

·药明康德

一次注射4周内见效，椎间盘突出疗法达到3期临床主要终点；只需每月一次，长效多肽疗法3期临床结果积极

▎药明康德内容团队编辑椎间盘突出疗法达到3期临床主要终点 Ferring Pharmaceuticals及其临床开发合作伙伴生化工业株式会社（Seikagaku）今天宣布了一项3期临床试验数据分析结果，该分析评估了SI-6603（通用名：condoliase）治疗与腰椎间盘突出（LDH）相关的坐骨神经腿痛方面的早期治疗结果。试验结果显示，研究达到主要终点，接受一剂SI-6603注射的LDH患者最严重腿痛获得显著改善。在这项双盲、模拟注射对照的3期临床中，LDH患者被随机分配接受单次椎间盘内注射SI-6603或模拟注射，随后进行52周的观察。修正意向治疗（mITT）人群包括341名参与者（SI-6603组169人；模拟注射组172人）。研究达到了其主要终点，显示第13周最严重腿痛的改善显著优于模拟注射组（最小二乘均值[LSM]差异：-7.5；p=0.0263），并在第4周（-6.0；p=0.0418）和第6周（-7.4；p=0.0146）就已显示出显著差异。 SI-6603含有condoliase作为其活性药物成分，是一种用于治疗与腰椎间盘突出相关的坐骨神经痛的在研药物，通过单次、直接椎间盘内注射来实现。SI-6603通过减轻神经根压迫从而减轻疼痛。它已经在日本获批上市，商品名为Hernicore。只需每月一次，长效肢端肥大症疗法3期临床结果积极 Camurus公司今日宣布了为期52周的开放标签3期临床试验ACROINNOVA 2的最终积极顶线结果，该研究评估了公司每月一次的皮下注射长效奥曲肽（CAM2029）的安全性和有效性。主要终点是52周治疗期间的安全性。皮下注射奥曲肽长效制剂耐受性良好，其长期安全性与作为标准治疗（SoC）的第一代生长抑素受体配体（SRL）缓释奥曲肽和兰瑞肽一致，没有发现新的安全信号。最常见的不良事件（AE）是轻度至中度的注射部位反应和胃肠道事件。没有与奥曲肽皮下长效制剂相关的严重不良事件。一名患者发生了与治疗相关的胆结石（中度）严重不良事件，症状已解决，该患者继续参与试验。有两名患者（1.5%）因不良事件停药；一例为轻度抑郁，另一例为轻度注射部位出血。 ACROINNOVA 2研究包括多个次要终点，包括生化控制率、症状评分和几项患者报告的结果。奥曲肽皮下长效制剂治疗与标准治疗相比，在总体人群中使缓解率显著提高了12.7%（95% CI：5.5%，19.9%），在新确诊患者中提高了22.8%（95% CI：11.6，33.9）。肢端肥大症通常由垂体腺瘤产生过量的生长激素并刺激胰岛素样生长因子-1（IGF-1）水平升高引起。这会导致骨骼和组织的异常生长，手、脚、面部特征和内脏器官增大，以及疲劳、关节痛、头痛、视野缺损、过度出汗和感觉异常等症状。奥曲肽皮下长效制剂CAM2029是一种即用型皮下注射奥曲肽，正在开发用于治疗肢端肥大症、胃肠胰腺神经内分泌肿瘤（GEP-NET）和多囊性肝病（PLD）。CAM2029旨在增强奥曲肽的暴露并方便每月一次使用预填充自动注射笔进行自我注射。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024. Retrieved July 15, 2024, from https://www.businesswire.com/news/home/20240715003804/en [2] Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients. Retrieved July 15, 2024, from https://www.prnewswire.com/news-releases/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients-302196596.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期临床结果临床成功